Elevated cellular immune responses and interferon-gamma release after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis

J Infect Dis. 1995 Jun;171(6):1683-7. doi: 10.1093/infdis/171.6.1683.

Abstract

Cellular immune responses to filarial antigens were examined in persons before and 1 year after beginning treatment with diethylcarbamazine (DEC). The subjects (17 microfilaremics, 13 asymptomatic amicrofilaremics, and 13 with elephantiasis) had not responded to Brgia malayi adult worm antigen (BmA) before chemotherapy. T cell proliferative responses to BmA improved significantly after therapy in the 3 clinical groups (P < .05) but was highest in the elephantiasis patients and asymptomatic amicrofilareimics. Cytokine release profiles after stimulation with parasite antigen were analyzed. Production of interferon (IFN)-gamma by BmA-stimulated mononuclear cells increased significantly after DEC treatment (geometric mean, 39.6-55.7 U/mL; P < .05), largely due to improved responses in elephantiasis patients and asymptomatic amicrofilaremics. In contrast, BmA-induced interleukin (IL)-4 release did not change significantly in these same patients after treatment. Thus, both microfilaremic and amicrofilaremic infections with B. malayi are associated with similar down-regulation of proliferative T cell function and IFN-gamma release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antigens, Helminth / immunology
  • Brugia malayi / immunology
  • Diethylcarbamazine / therapeutic use*
  • Drug Administration Schedule
  • Elephantiasis, Filarial / drug therapy*
  • Female
  • Humans
  • Immunity, Cellular*
  • Interferon-gamma / metabolism*
  • Lymphocyte Activation
  • Male
  • T-Lymphocytes / immunology
  • Tuberculin / immunology

Substances

  • Antigens, Helminth
  • Tuberculin
  • Interferon-gamma
  • Diethylcarbamazine